Mark Sostek is joining San Francisco-based drug developer OrphoMed as chief medical officer. Sostek most recently worked at Pfizer (NYSE: [[ticker:PFE]]) in its inflammation and immunology research unit. Before that, he was global clinical leader for gastrointestinal programs at AstraZeneca (NYSE: [[ticker:AZN]]). OrphoMed’s lead drug candidate, ORP-101, is in early-stage clinical testing for irritable bowel syndrome with diarrhea.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
